Skip to main content
PMC home page
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2009 Oct 17;10(6):419–422. doi: 10.1007/s10194-009-0164-9

Topiramate in migraine progression

Luigi Ruiz 1,✉, Delfina Ferrandi 1
PMCID: PMC3476219  PMID: 19838625

Abstract

Increasing evidence shows that migraine, typically considered as an episodic disease, is a chronic and, in some patients, progressive disorder. Among neuromodulators used for migraine prevention, topiramate has a high level of evidence-based efficacy. Through its wide range of mechanisms of action topiramate increases the activation threshold resulting in neuronal stabilization and thereby reducing cortical neurons hyperexcitability, which is believed to be an important electrophysiological feature underlying the pathogenesis of epilepsy and migraine. Recent studies show that migraineurs have subclinical structural brain changes and persistent alteration of pain perception, in some cases correlated with the duration of the disease and the frequency of attacks that might play a role in the transformation of episodic migraine to chronic forms. An early and prolonged preventive treatment might reduce the risk of such transformation. Recent evidence suggests that topiramate, by reducing migraine frequency and use of acute medication, may prevent the negative progression of migraine. Furthermore, two recently completed multicenter, randomised, placebo-controlled trials have shown that treatment with topiramate 100 mg/day is effective and well tolerated in patients already progressed to chronic migraine and difficult to treat conditions associated with medication-overuse. Topiramate seems to be a preventive treatment, which might be able to act at different levels of the migraine cycle: reduction of frequency in episodic migraine, prevention, and treatment of chronic migraine.

Keywords: Topiramate, Chronic migraine, Preventive treatment, Migraine progression

Full Text

The Full Text of this article is available as a PDF (158.7 KB).

Conflict of interest

None.

Contributor Information

Luigi Ruiz, Phone: +39-131-206623, FAX: +39-131-206419, Email: lruiz@ospedale.al.it.

Delfina Ferrandi, Email: dferrandi@ospedale.al.it.

References

  • 1.Welch KMA, Nagesh V, Aurora SK, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41:629–637. doi: 10.1046/j.1526-4610.2001.041007629.x. [DOI] [PubMed] [Google Scholar]
  • 2.Bigal ME, Lipton RB. The chronification of headache. Concepts and mechanisms of migraine chronification. Headache. 2008;48:7–15. doi: 10.1111/j.1526-4610.2007.00969.x. [DOI] [PubMed] [Google Scholar]
  • 3.Leão AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol. 1944;7:359–390. doi: 10.1152/jn.1947.10.6.409. [DOI] [PubMed] [Google Scholar]
  • 4.Kunkler PE, Kraig RP. Hippocampal spreading depression bilaterally activates the caudal trigeminal nucleus in rodents. Hippocampus. 2003;13:835–844. doi: 10.1002/hipo.10139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lauritzen M, Jorgensen MB, Diemer NH, et al. Persistent oligoemia of rat cerebral cortex in the wake of spreading depression. Ann Neurol. 1982;12:469–474. doi: 10.1002/ana.410120510. [DOI] [PubMed] [Google Scholar]
  • 6.Leao A, Morison R. Propagation of spreading cortical depression. J Neurophysiol. 1945;8:33–45. [Google Scholar]
  • 7.Milner PM (1958) Note on a possible correspondence between the scotomas of migraine and spreading depression of Leao. Electroencephalogr Clin Neurophysiol Supp 110:705 [DOI] [PubMed]
  • 8.Cao Y, Welch KM, Aurora S, et al. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol. 1999;56:548–554. doi: 10.1001/archneur.56.5.548. [DOI] [PubMed] [Google Scholar]
  • 9.Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA. 2001;98:4687–4692. doi: 10.1073/pnas.071582498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59:652–661. doi: 10.1002/ana.20778. [DOI] [PubMed] [Google Scholar]
  • 11.Kruit MC, Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004;291:427–434. doi: 10.1001/jama.291.4.427. [DOI] [PubMed] [Google Scholar]
  • 12.Lipton RB, Pan J. Is migraine a progressive brain disease? JAMA. 2004;291:493–494. doi: 10.1001/jama.291.4.493. [DOI] [PubMed] [Google Scholar]
  • 13.Granziera C, DaSilva AFM, Snyder J et al (2006) Anatomical alterations of the visual motion processing network in migraine with and without aura. PLoS Med 3(10):e402. doi:10.1371/journal.pmed.0030402 [DOI] [PMC free article] [PubMed]
  • 14.Montagna P, Cevoli S, Marzocchi N, et al. The genetics of chronic headaches. Neurol Sci. 2003;24(suppl 2):S51–S56. doi: 10.1007/s100720300041. [DOI] [PubMed] [Google Scholar]
  • 15.Welsh KMA, Goadsby PJ. Chronic daily headache. Curr Opin Neurol. 2002;l15:287–295. doi: 10.1097/00019052-200206000-00011. [DOI] [PubMed] [Google Scholar]
  • 16.Kitaj MB, Klink M. Pain thresholds in daily transformed migraine versus episodic migraine headache patients. Headache. 2005;45:992–998. doi: 10.1111/j.1526-4610.2005.05179.x. [DOI] [PubMed] [Google Scholar]
  • 17.Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106:81–89. doi: 10.1016/S0304-3959(03)00293-8. [DOI] [PubMed] [Google Scholar]
  • 18.Limmroth V, Biondi D, Pfeil J et al (2007) Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 47:13–21 [DOI] [PubMed]
  • 19.Shank RP, Maryanoff BE. Molecular pharmacodyynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther. 2008;14:120–142. doi: 10.1111/j.1527-3458.2008.00041.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport. 2005;16:1383–1387. doi: 10.1097/01.wnr.0000175250.33159.a9. [DOI] [PubMed] [Google Scholar]
  • 21.Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia. 2004;24:1049–1056. doi: 10.1111/j.1468-2982.2004.00767.x. [DOI] [PubMed] [Google Scholar]
  • 22.Brandes JL, Saper JR, Diamond M, et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965–973. doi: 10.1001/jama.291.8.965. [DOI] [PubMed] [Google Scholar]
  • 23.Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis—results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943–950. doi: 10.1007/s00415-004-0464-6. [DOI] [PubMed] [Google Scholar]
  • 24.Silberstein SD, Neto W, Schmitt J et al (2004) Topiramate in migraine prevention: results from a large controlled trial. Arch Neurol 61:490–495 [DOI] [PubMed]
  • 25.Rapoport A, Mauskop A, Diener HC, et al. Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache. 2006;46:1151–1160. doi: 10.1111/j.1526-4610.2006.00506.x. [DOI] [PubMed] [Google Scholar]
  • 26.Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007;6:1054–1062. doi: 10.1016/S1474-4422(07)70272-7. [DOI] [PubMed] [Google Scholar]
  • 27.Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med. 2008;9:175–185. doi: 10.1111/j.1526-4637.2007.00389.x. [DOI] [PubMed] [Google Scholar]
  • 28.Mosek A, Dano M. Topiramate in the treatment of refractory chronic daily headache: an open trial. J Headache Pain. 2005;6:77–80. doi: 10.1007/s10194-005-0155-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol. 2005;28:277–279. doi: 10.1097/01.wnf.0000192136.46145.44. [DOI] [PubMed] [Google Scholar]
  • 30.Silvestrini M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23:820–824. doi: 10.1046/j.1468-2982.2003.00592.x. [DOI] [PubMed] [Google Scholar]
  • 31.Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–180. doi: 10.1111/j.1526-4610.2006.00684.x. [DOI] [PubMed] [Google Scholar]
  • 32.Diener H-C, Bussone G, Van Oene JC et al (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814–823 [DOI] [PubMed]
  • 33.Silberstein S, Diener HC, Lipton R et al (2008) Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache 48:1087–1095 [DOI] [PubMed]
  • 34.Ramadan NM, Silberstein SD, Freitag FG et al (2000) Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of Headache 597 migraine. Am Acad Neurol, pp 1–55. Available at http://www.aan.com/professionals/practice/pdfs/gl0090.pdf. Accessed 4 June 2006
  • 35.Evers S, Afra J, Frese A et al (2006) EFNS guideline on the drug treatment of migraine—report of an EFNS task force. Eur J Neurol 13:560–572 [DOI] [PubMed]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES